Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case–Control Study

2009199 citationsJournal Articlebronze Open Access

Authors

Garnet L. Anderson · Cancer Research Center

Martin McIntosh · Fred Hutch Cancer Center

LieLing Wu · Cancer Research Center

Matt J. Barnett · University of Pennsylvania

Gary E. Goodman · Diazyme (United States)

Jason D. Thorpe · Fred Hutch Cancer Center

Lindsay Bergan ·

Abstract

Serum concentrations of CA125, HE4, and mesothelin may provide evidence of ovarian cancer 3 years before clinical diagnosis, but the likely lead time associated with these markers appears to be less than 1 year.

Topics & Keywords

Ovarian cancer diagnosis and treatment Intraperitoneal and Appendiceal Malignancies Renal and related cancers

UN Sustainable Development Goals

Reduced inequalities

Publication Details

Published in: JNCI Journal of the National Cancer Institute

Volume 102, Issue 1, pp. 26-38

DOI: 10.1093/jnci/djp438

Field-Weighted Citation Impact: 25.30